Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy Male Subjects. A Randomised, Doubleblind, Placebo-controlled, Monocentre, First-In-Human Study

Trial Profile

Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy Male Subjects. A Randomised, Doubleblind, Placebo-controlled, Monocentre, First-In-Human Study

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRG-110 (Primary)
  • Indications Heart failure; Ischaemia
  • Focus Adverse reactions; First in man
  • Sponsors Servier
  • Most Recent Events

    • 16 Oct 2019 According to a miRagen Therapeutics media release, data of this trial will be included in an oral presentation detailing the MRG-110 program provided by Dr. Rusty L. Montgomery, Director of Research, miRagen Therapeutics, today at the 15th annual meeting of the Oligonucleotide Therapeutics Society, which is being held in Munich, Germany. The presentation will be available on the scientific publications page of the Companys website following the presentation.
    • 16 Oct 2019 Results presented in a miRagen Therapeutics Media Release.
    • 25 Apr 2019 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top